Abstract
Importance Biomarkers can potentially improve the diagnosis, monitoring, and treatment of posttraumatic stress disorder (PTSD). However, PTSD biomarkers that are scalable and easily integrated into real-world clinical settings have not been identified.
Objective To triangulate phenotypic and genomic evidence from a health system biobank with a goal of identifying scalable and clinically relevant biomarkers for PTSD.
Design, setting, and participants The analysis was conducted between June to November 2024 using genomic samples and laboratory test results recorded in the Mass General Brigham (MGB) Health System. The analysis included 23,743 European ancestry participants from the nested MGB Biobank study.
Exposures The first exposure was polygenic risk score (PRS) for PTSD, calculated using the largest available European ancestry genome-wide association study (GWAS), employing a Bayesian polygenic scoring method. The second exposure was a clinical diagnosis of PTSD, determined by the presence of two or more qualifying PTSD phecodes in the longitudinal electronic health records (EHR).
Main outcomes and measures The primary outcomes were the inverse normal quantile transformed, median lab values of 241 laboratory traits with non-zero h2SNPestimates.
Results Sixteen unique laboratory traits across the cardiometabolic, hematologic, hepatic, and immune systems were implicated in both genomic and phenotypic lab-wide association scans (LabWAS). Two-sample Mendelian randomization analyses provided evidence of potential unidirectional causal effects of PTSD liability on five laboratory traits.
Conclusion and relevance These findings demonstrate the potential of a triangulation approach to uncover scalable and clinically relevant biomarkers for PTSD.
Question Is genetic liability or diagnosis of PTSD associated with clinical laboratory measures?
Findings Among European ancestry participants in the MGB Biobank, we identified 16 unique laboratory traits in cardiometabolic, hematologic, hepatic, and immune systems that were both genetically and phenotypically associated with PTSD, with five markers demonstrating potential unidirectional causal effects of PTSD liability.
Meaning Our findings reveal associations between PTSD and laboratory markers across multiple physiological systems, with evidence suggesting possible unidirectional causal effects of PTSD liability on cardiometabolic, hematologic, and hepatic markers.
Competing Interest Statement
JWS is a member of the Scientific Advisory Board of Sensorium Therapeutics (with options), has received a consulting fee from Data Driven, Inc., and has received grant support from Biogen, Inc. KCK receives consulting fees from the US Department of Justice and Covington Burling LLP and has royalites from Guilford Press and Oxford University Press.
Funding Statement
Financial support for the Psychiatric Genomics Consortium (PGC) PTSD Working Group was provided by the Cohen Veterans Bioscience, Stanley Center for Psychiatric Research at the Broad Institute, One Mind, and the National Institute of Mental Health (NIMH; R01MH106595, R01MH124847, R01MH124851, R01MH118233). JHL is individually supported by NIDDK K23 DK131345. YHL and NS are supported by the Broad Trauma Initiative. ALED is individually supported by NIMH T32 MH 017119.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was conducted under a protocol approved by the Mass General Brigham (MGB) Institutional Review Board (# 2019P003696).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos